The National Agency for the Safety of Medicines and Health Products (ANSM) has launched a pharmacovigilance survey on desonumab - marketed under the name Prolia - a drug prescribed to fight osteoporosis. 90,000 French patients benefit from this treatment that fights against bone loss. The molecule is prescribed in case of failure or intolerance to bisphosphonates (Fosamax®, Actonel®), the first-line treatment at home.
Problem? Prolia is suspected of increasing the risk of multiple fractures upon discontinuation of treatment. A kind of harmful rebound effect that has already affected several menopausal women, even if it is rare. "Cases of patients, especially in Switzerland, who had developed multiple vertebral fractures when Prolia treatment was discontinued have been reported", says the ANSM. In France, 11 cases have been reported since its marketing in 2011. The health agency must therefore investigate to establish the existence or not of a causal link between the discontinuation of Prolia treatment and the occurrence of these vertebral fractures. multiple.
If you are scheduled for an injection soon (it happens every six months), do not cancel it without talking to your doctor. The French Society of Rheumatology (SFR) and the Research and Information Group on Osteoporosis (GRIO) recommend, "considering the bone loss and the potential risk of multiple vertebral fractures upon discontinuation of treatment, 'to establish, in relay of Prolia, a treatment by oral bisphosphonate or injectable for a period of 6 to 12 months'. Pending the results of the survey of health authorities, which should be known next fall.
Every year in France, more than 376,000 fractures are due to osteoporosis. And the number of deaths after a fracture related to this insidious disease exceeds that of road accidents.